(25.06.2019, 15:31)Banker schrieb: Keine ordentliche Produktpipeline.............
Das kam hier schon öfter - das stimmt aber so nicht:
Replacing billions of Humira revenue is no small task. Two potential blockbusters make up the core of AbbVie's plans to diversify away from Humira, immunology drugs Skyrizi and Upadacitinib, or Upa.
Both drugs are successor medicines for Humira and were expected to launch in 2019. Those plans remain on track. While Upa is expected to be approved by the FDA in the third quarter, Skyrizi has already been approved by the U.S., Canada, and Japan, with Europe expected to approve soon.
The company expects to achieve $150 million in Skyrizi sales in 2019 (mostly second half of the year). A multi-year ramp is expected to eventually bring sales to $5 billion to $6 billion per year. Upa is also expected to deliver $5 billion to $6 billion in annual peak sales by 2025. For context, AbbVie's 2018 sales were $32.8 billion.